Top

Published in:

01-08-2014 | Review

Tumor protein D52 (TPD52) and cancer—oncogene understudy or understudied oncogene?

Authors: Jennifer A. Byrne, Sarah Frost, Yuyan Chen, Robert K. Bright

Published in: Tumor Biology | Issue 8/2014

Abstract

The Tumor protein D52 (TPD52) gene was identified nearly 20 years ago through its overexpression in human cancer, and a substantial body of data now strongly supports TPD52 representing a gene amplification target at chromosome 8q21.13. This review updates progress toward understanding the significance of TPD52 overexpression and targeting, both in tumors known to be characterized by TPD52 overexpression/amplification, and those where TPD52 overexpression/amplification has been recently or variably reported. We highlight recent findings supporting microRNA regulation of TPD52 expression in experimental systems and describe progress toward deciphering TPD52’s cellular functions, particularly in cancer cells. Finally, we provide an overview of TPD52’s potential as a cancer biomarker and immunotherapeutic target. These combined studies highlight the potential value of genes such as TPD52, which are overexpressed in many cancer types, but have been relatively understudied.

Khleif SN, Doroshow JH, Hait WN, AACR-FDA-NCI Cancer Biomarkers Collaborative. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res. 2010;16:3299–318. doi:10.1158/1078-0432.CCR-10-0880.CrossRef

Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 2012;72:6097–101. doi:10.1158/0008-5472.CAN-12-3232.PubMedCentralCrossRef

Edwards AM, Isserlin R, Bader GD, Frye SV, Willson TM, Yu FH. Too many roads not taken. Nature. 2011;470:163–5. doi:10.1038/470163a.CrossRef

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323–37. doi:10.1158/1078-0432.CrossRef

Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–13.CrossRef

Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495–501. doi:10.1038/nature12912.PubMedCentralCrossRef

Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338:221. doi:10.1126/science.1226344.PubMedCentralCrossRef

Boutros R, Fanayan S, Shehata M, Byrne JA. The tumor protein D52 family: many pieces, many puzzles. Biochem Biophys Res Commun. 2004;325:1115–21.CrossRef

Shehata M, Weidenhofer J, Thamotharampillai K, Hardy JR, Byrne JA. Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays. Crit Rev Oncog. 2008;14:33–55.CrossRef

10.

Byrne JA, Tomasetto C, Garnier JM, Rouyer N, Mattei MG, Bellocq JP, et al. A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence. Cancer Res. 1995;55:2896–903.

11.

Chen SL, Maroulakou IG, Green JE, Romano-Spica V, Modi W, Lautenberger J, et al. Isolation and characterization of a novel gene expressed in multiple cancers. Oncogene. 1996;12:741–51.

12.

Parente JA, Goldenring JR, Petropoulos AC, Hellman U, Chew CS. Purification, cloning, and expression of a novel, endogenous, calcium-sensitive, 28-kDa phosphoprotein. J Biol Chem. 1996;271:20096–101.CrossRef

13.

Groblewski GE, Wishart MJ, Yoshida M, Williams JA. Purification and identification of a 28-kDa calcium-regulated heat-stable protein. A novel secretagogue-regulated phosphoprotein in exocrine pancreas. J Biol Chem. 1996;271:31502–7.CrossRef

14.

Proux V, Provot S, Felder-Schmittbuhl M-P, Laugier D, Calothy G, Marx M. Characterization of a leucine zipper-containing protein identified by retroviral insertion in avian neuroretina cells. J Biol Chem. 1996;271:30790–7.CrossRef

15.

Shehata M, Bièche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, et al. Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin Cancer Res. 2008;14:5050–60.CrossRef

16.

Tennstedt P, Bölch C, Strobel G, Minner S, Burkhardt L, Grob T, et al. Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. Int J Oncol. 2014;44:609–15. doi:10.3892/ijo.2013.2200.

17.

Roslan N, Bièche I, Bright RK, Lidereau R, Chen Y, Byrne JA. TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol. Carcinog. 2013.

18.

Byrne JA, Chen Y, Martin La Rotta N, Peters GB. Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study. Genes Cancer. 2012;3:87–101.PubMedCentralCrossRef

19.

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.CrossRef

20.

Aure MR, Steinfeld I, Baumbusch LO, Liestøl K, Lipson D, Nyberg S, et al. Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data. PLoS ONE. 2013;8:e53014. doi:10.1371/journal.pone.0053014.PubMedCentralCrossRef

21.

Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, et al. A refined molecular taxonomy of breast cancer. Oncogene. 2012;31:1196–206.PubMedCentralCrossRef

22.

Cornen S, Guille A, Adélaïde J, Addou-Klouche, Finetti P, Saade M-R, et al. Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. PLOS One. 2014. doi:10.1371/journal.pone.0081843.

23.

Wilson KS, Roberts H, Leek R, Harris AL, Geradts J. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol. 2002;161:1171–85.PubMedCentralCrossRef

24.

Landis MD, Seachrist DD, Montanez-Wiscovich ME, Danielpour D, Keri RA. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene. 2005;24:5173–90.PubMedCentralCrossRef

25.

Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Oncogene. 2006;25:3325–34.PubMedCentralCrossRef

26.

Whiteaker JR, Zhang H, Zhao L, et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res. 2007;6:3962–75.CrossRef

27.

Chen H, Pimienta G, Gu Y, et al. Proteomic characterization of Her2/neu-overexpressing breast cancer cells. Proteomics. 2010;10:3800–10.CrossRef

28.

Kourtidis A, Jain R, Carkner RD, Eifert C, Brosnan MJ, Conklin DS. An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer Res. 2010;70:1783–92.PubMedCentralCrossRef

29.

Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol. 2009;35:537–46.

30.

Ross AE, Marchionni L, Vuica-Ross M, Cheadle C, Fan J, Berman DM, et al. Gene expression pathways of high grade localized prostate cancer. Prostate. 2011;71:1568–77.

31.

Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS ONE. 2008;3:e2318. doi:10.1371/journal.pone.0002318.PubMedCentralCrossRef

32.

Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, et al. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013;119:2405–12. doi:10.1002/cncr.27954.CrossRef

33.

Chen SL, Zhang XK, Halverson DO, Byeon MK, Schweinfest CW, Ferris DK, et al. Characterization of human N8 protein. Oncogene. 1997;15:2577–88.CrossRef

34.

Rohrbeck A, Neukirchen J, Rosskopf M, Pardillos GG, Geddert H, Schwalen A, et al. Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med. 2008;6:69. doi:10.1186/1479-5876-6-69.PubMedCentralCrossRef

35.

Bangur CS, Switzer A, Fan L, Marton MJ, Meyer MR, Wang T. Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene. 2002;21:3814–25.CrossRef

36.

Ziv T, Barnea E, Segal H, Sharon R, Beer I, Admon A. Comparative proteomics of small cell lung carcinoma. Cancer Biomark. 2006;2:219–34.

37.

Boelens MC, van den Berg A, Fehrmann RS, Geerlings M, de Jong WK, te Meerman GJ, et al. Current smoking-specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer. J Pathol. 2009;218:182–91. doi:10.1002/path.2520.CrossRef

38.

Hanada S, Kakehashi A, Nishiyama N, Wei M, Yamano S, Chung K, et al. Myristoylated alanine-rich C-kinase substrate as a prognostic biomarker in human primary lung squamous cell carcinoma. Cancer Biomark. 2013;13:289–98. doi:10.3233/CBM-130354.

39.

Zhang H, Liu Q, Zimmerman LJ, Ham AJ, Slebos RJ, Rahman J, et al. Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol Cell Proteomics. 2011;10:M110.006593. doi:10.1074/mcp.M110.006593.PubMedCentralCrossRef

40.

Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med. 2007;13:361–6.CrossRef

41.

Zhao P, Zhong W, Ying X, Yao B, Yuan Z, Fu J, et al. Comparative proteomic analysis of anti-benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide-transformed and normal human bronchial epithelial G0/G1 cells. Chem Biol Interact. 2010;186:166–73.CrossRef

42.

Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450:893–8.PubMedCentralCrossRef

43.

Marescalco MS, Capizzi C, Condorelli DF, Barresi V. Genome-wide analysis of recurrent copy-number alterations and copy-neutral loss of heterozygosity in head and neck squamous cell carcinoma. J Oral Pathol Med. 2013. doi:10.1111/jop.12087.

44.

Cheng L, Wang P, Yang S, Yang Y, Zhang Q, Zhang W, et al. Identification of genes with a correlation between copy number and expression in gastric cancer. BMC Med Genomics. 2012;5:14. doi:10.1186/1755-8794-5-14.PubMedCentralCrossRef

45.

Aquino PF, Fischer JS, Neves-Ferreira AG, Perales J, Domont GB, Araujo GD, et al. Are gastric cancer resection margin proteomic profiles more similar to those from controls or tumors? J Proteome Res. 2012;11:5836–42. doi:10.1021/pr300612x.

46.

Williams TA, Monticone S, Morello F, Liew CC, Mengozzi G, Pilon C, et al. Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro. Hypertension. 2010;55:1468–75. doi:10.1161/HYPERTENSIONAHA.110.150318.CrossRef

47.

Herbet M, Salomon A, Feige JJ, Thomas M. Acquisition order of Ras and p53 gene alterations defines distinct adrenocortical tumor phenotypes. PLoS Genet. 2012;8:e1002700. doi:10.1371/journal.pgen.1002700.PubMedCentralCrossRef

48.

Ozaki T, Paulussen M, Poremba C, Brinkschmidt C, Rerin J, Ahrens S, et al. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Gene Chromosome Cancer. 2001;32:164–71.CrossRef

49.

Stock C, Kager L, Fink FM, Gadner H, Ambros PF. Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer. 2000;28:329–36.CrossRef

50.

Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009;27:2503–8. doi:10.1200/JCO.2008.17.9762.CrossRef

51.

Machado I, López-Guerrero JA, Calabuig-Fariñas S, Hardy JR, Scotlandi K, Picci P, et al. Clinical significance of tumor protein D52 immunostaining in a large series of Ewing’s sarcoma family of tumors. Pediatr Dev Pathol. 2011;14:255–6. doi:10.2350/11-01-0956-LET.1.CrossRef

52.

Li G, Cai Z, Zhang Y, Ru M, Ji F. Screening for pathogenesis-related genes of osteosarcoma using gene microarray. Chin J Cancer Biother. 2007;14:428–34.

53.

Zou C, Shen J, Tang Q, Yang Z, Yin J, Li Z, et al. Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis. Cancer. 2012;118:1845–55. doi:10.1002/cncr.26486.CrossRef

54.

Flores RJ, Li Y, Yu A, Shen J, Rao PH, Lau SS, et al. A systems biology approach reveals common metastatic pathways in osteosarcoma. BMC Syst Biol. 2012;6:50. doi:10.1186/1752-0509-6-50.PubMedCentralCrossRef

55.

Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Investig. 2011;91:1195–205. doi:10.1038/labinvest.2011.72.CrossRef

56.

Machado I, Alberghini M, Giner F, Corrigan M, O’Sullivan M, Noguera R, et al. Histopathological characterization of small cell osteosarcoma with immunohistochemistry and molecular genetic support. A study of 10 cases. Histopathology. 2010;57:162–7.CrossRef

57.

Barbaric D, Byth K, Dalla-Pozza L, Byrne JA. Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: clinical and sample considerations. Leuk Res. 2006;30:1355–63.CrossRef

58.

Kang H, Wilson CS, Harvey RC, Chen IM, Murphy MH, Atlas SR, et al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood. 2012;119:1872–81. doi:10.1182/blood-2011-10-382861.PubMedCentralCrossRef

59.

Mattison J, Kool J, Uren AG, de Ridder J, Wessels L, Jonkers J, et al. Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. Cancer Res. 2010;70:883–95.PubMedCentralCrossRef

60.

Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45:1134–40. doi:10.1038/ng.2760.CrossRef

61.

Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, et al. Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell. 2013;23:9–22. doi:10.1016/j.ccr.2012.11.006.CrossRef

62.

Wang K, Lim HY, Shi S, Lee J, Deng S, Xie T, et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology. 2013;58:706–17. doi:10.1002/hep.26402.CrossRef

63.

March HN, Rust AG, Wright NA, ten Hoeve J, de Ridder J, Eldridge M, et al. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet. 2011;43:1202–9. doi:10.1038/ng.990.PubMedCentralCrossRef

64.

Gottwein E, Corcoran DL, Mukherjee N, Skalsky RL, Hafner M, Nusbaum JD, et al. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe. 2011;10:515–26. doi:10.1016/j.chom.2011.09.012.PubMedCentralCrossRef

65.

Haecker I, Gay LA, Yang Y, Hu J, Morse AM, McIntyre LM, et al. Ago HITS-CLIP expands understanding of Kaposi’s sarcoma-associated herpesvirus miRNA function in primary effusion lymphomas. PLoS Pathog. 2012;8:e1002884. doi:10.1371/journal.ppat.1002884.PubMedCentralCrossRef

66.

Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non-small cell lung cancer cell lines. PLoS ONE. 2009;4:e6677. doi:10.1371/journal.pone.0006677.PubMedCentralCrossRef

67.

Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Röh S, Hoffmann R, et al. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics. 2011;10:M111.010462. doi:10.1074/mcp.M111.010462.PubMedCentralCrossRef

68.

Bader AG. miR-34—a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120. doi:10.3389/fgene.2012.00120.PubMedCentralCrossRef

69.

Templin T, Paul S, Amundson SA, Young EF, Barker CA, Wolden SL, et al. Radiation-induced micro-RNA expression changes in peripheral blood cells of radiotherapy patients. Int J Radiat Oncol Biol Phys. 2011;80:549–57. doi:10.1016/j.ijrobp.2010.12.061.PubMedCentralCrossRef

70.

Ummanni R, Teller S, Junker H, Zimmermann U, Venz S, Scharf C, et al. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J. 2008;275:5703–13.CrossRef

71.

Zhang H, Wang J, Pang B, Liang RX, Li S, Huang PT, et al. PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer Res. 2007;67:8906–13.CrossRef

72.

Zhang D, He D, Xue Y, Wang R, Wu K, Xie H, et al. PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res. 2011;71:2193–202.PubMedCentralCrossRef

73.

Li L, Zhang D, Zhang L, Zhu G, Sun Y, Wu K, et al. PrLZ expression is associated with the progression of prostate cancer LnCaP cells. Mol Carcinog. 2009;48:432–40.CrossRef

74.

Li L, Xie H, Liang L, Gao Y, Zhang D, Fang L, et al. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. Carcinogenesis. 2013;34:257–67. doi:10.1093/carcin/bgs337.PubMedCentralCrossRef

75.

Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, et al. Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol Cancer Res. 2007;5:133–44.CrossRef

76.

Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, et al. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol. 2012;8:646–54. doi:10.1038/nchembio.965.PubMedCentralCrossRef

77.

Sims AH, Finnon P, Miller CJ, Bouffler SD, Howell A, Scott D, et al. TPD52 and NFKB1 gene expression levels correlate with G2 chromosomal radiosensitivity in lymphocytes of women with and at risk of hereditary breast cancer. Int J Radiat Biol. 2007;83(6):409–20.CrossRef

78.

Niu N, Qin Y, Fridley BL, Hou J, Kalari KR, Zhu M, et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 2010;20:1482–92. doi:10.1101/gr.107672.110.PubMedCentralCrossRef

79.

Adamson B, Smogorzewska A, Sigoillot FD, King RW, Elledge SJ. A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat Cell Biol. 2012;14:318–28. doi:10.1038/ncb2426.PubMedCentralCrossRef

80.

Chen Y, Kamili A, Hardy JR, Groblewski GE, Khanna KK, Byrne JA. Tumor protein D52 represents a negative regulator of ATM protein levels. Cell Cycle. 2013;12:3083–97. doi:10.4161/cc.26146.CrossRef

81.

Kaspar KM, Thomas DD, Taft WB, Takeshita E, Weng N, Groblewski GE. CaM kinase II regulation of CRHSP-28 phosphorylation in cultured mucosal T84 cells. Am J Physiol Gastrointest Liver Physiol. 2003;285:G1300–9.

82.

Chew CS, Chen X, Zhang H, Berg EA, Zhang H. Calcium/calmodulin-dependent phosphorylation of tumor protein D52 on serine residue 136 may be mediated by CAMK2delta6. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1159–72.PubMedCentralCrossRef

83.

Thomas DD, Martin CL, Weng N, Byrne JA, Groblewski GE. Tumor protein D52 expression and Ca2+-dependent phosphorylation modulates lysosomal membrane protein trafficking to the plasma membrane. Am J Physiol Cell Physiol. 2010;298:C725–39.PubMedCentralCrossRef

84.

Messenger SW, Thomas DD, Falkowski MA, Byrne JA, Gorelick FS, Groblewski GE. Tumor protein D52 controls trafficking of an apical endolysosomal secretory pathway in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol. 2013;305:G439–52.CrossRef

85.

Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights. 2007;1:1–48.PubMedCentral

86.

Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics. 2010;9:184–96.PubMedCentralCrossRef

87.

Hüttenhain R, Soste M, Selevsek N, Röst H, Sethi A, Carapito C, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med. 2012;4:142ra94. doi:10.1126/scitranslmed.3003989.PubMedCentralCrossRef

88.

Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics. 2007;6:1115–22.CrossRef

89.

Pedersen JW, Wandall HH. Autoantibodies as biomarkers in cancer. Lab Med. 2011;42:623–8.CrossRef

90.

Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO, et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun. 2001;1:4.

91.

Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res. 2011;10:85–96. doi:10.1021/pr100686b.PubMedCentralCrossRef

92.

Wang J, Barker K, Steel J, Park J, Saul J, Festa F, et al. A versatile protein microarray platform enabling antibody profiling against denatured proteins. Proteomics Clin Appl. 2013;7:378–83. doi:10.1002/prca.201200062.PubMedCentralCrossRef

93.

Mayer-Sonnenfeld T, Har-Noy M, Lillehei KO, Graner MW. Proteomic analyses of different human tumor-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL’s unique structure: CRCL vaccine proteome leads to unique structure. Int J Hyperthermia. 2013;29:520–7. doi:10.3109/02656736.2013.796529.CrossRef

94.

Payton LA, Lewis JD, Byrne JA, Bright RK. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol Immunother. 2008;57:799–811.CrossRef

95.

Bright JD, Schultz HN, Byrne JA, Bright RK. Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. Oncoimmunology. 2013;2:e25049.PubMedCentralCrossRef

96.

Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunol Immunother. 2009;58:1337–49.CrossRef

97.

Bright JD, Aldrich JF, Byrne JA, Bright RK. Vaccination with the prostate cancer over-expressed tumor self-protein TPD52 elicits protective tumor immunity and a potentially unique subset of CD8+ T cells. Austin J Clin Immunol. 2014, in press.

98.

Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, et al. Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine. 2009;27:1825–33.CrossRef

Title: Tumor protein D52 (TPD52) and cancer—oncogene understudy or understudied oncogene?
Authors: Jennifer A. Byrne
Sarah Frost
Yuyan Chen
Robert K. Bright
Publication date: 01-08-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 8/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2006-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2014

Molecular mechanism of TGF-β signaling pathway in colon carcinogenesis and status of curcumin as chemopreventive strategy

Prognostic value of PDCD6 polymorphisms and the susceptibility to bladder cancer

The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials

SchA–p85–FAK complex dictates isoform-specific activation of Akt2 and subsequent PCBP1-mediated post-transcriptional regulation of TGFβ-mediated epithelial to mesenchymal transition in human lung cancer cell line A549

Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy

The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer